Media coverage about Kadmon (NYSE:KDMN) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Kadmon earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave news stories about the company an impact score of 46.2188619660849 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Kadmon traded down $0.19, reaching $3.41, during midday trading on Wednesday, MarketBeat.com reports. The company had a trading volume of 847,560 shares, compared to its average volume of 868,778. The firm has a market cap of $302.57 million, a PE ratio of -2.40 and a beta of 3.67. Kadmon has a 12-month low of $2.05 and a 12-month high of $5.86.
Kadmon (NYSE:KDMN) last announced its quarterly earnings results on Tuesday, May 8th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.30) by $0.03. The business had revenue of $0.43 million for the quarter, compared to analysts’ expectations of $2.67 million. equities analysts anticipate that Kadmon will post -0.96 earnings per share for the current fiscal year.
Kadmon Company Profile
Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease.
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.